
    
      The proportion of subjects with detectable antibodies and antibody geometrical mean titers to
      9 HPV genotypes included in the Gardasil-9 vaccine will be assessed 1 and 6 months post-first
      dose and 1, 18 and 36 months post-second dose of vaccine.
    
  